0001760542 false 0001760542 2023-08-03 2023-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): August 3, 2023

 

HOOKIPA PHARMA INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38869   81-5395687

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(I.R.S. Employer

Identification No.)

 

350 Fifth Avenue, 72nd Floor

Suite 7240

 
New York, New York   10018
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +43 1 890 63 60

 

Not Applicable

Former name or former address, if changed since last report

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, $0.0001 par value per share HOOK The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On August 3, 2023, HOOKIPA Pharma Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.

 

The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the symbol “HOOK”.

 

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has automatically been afforded a 180-calendar day period, or until January 30, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard will be met if the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day period. If the Company is not in compliance by January 30, 2024, the Company may be afforded a second 180-calendar day period to regain compliance if it meets certain requirements.

 

The Company intends to monitor the closing bid price of its common stock and is currently evaluating its options for regaining compliance, which could include a reverse stock split of the Company’s common stock.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 4, 2023 HOOKIPA Pharma, Inc.
   
  By: /s/ Joern Aldag
    Joern Aldag
    Chief Executive Officer
(Principal Executive Officer)

 

 

 

v3.23.2
Cover
Aug. 03, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 03, 2023
Entity File Number 001-38869
Entity Registrant Name HOOKIPA PHARMA INC.
Entity Central Index Key 0001760542
Entity Tax Identification Number 81-5395687
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 350 Fifth Avenue, 72nd Floor
Entity Address, Address Line Two Suite 7240
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10018
City Area Code +43
Local Phone Number 1 890 63 60
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.0001 par value per share
Trading Symbol HOOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true

HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more HOOKIPA Pharma Charts.
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more HOOKIPA Pharma Charts.